When was Sophia Genetics founded?

Sophia Genetics was founded in 2011 and raised its 1st funding round 2 years after it was founded.

Where is Sophia Genetics located?

Sophia Genetics is headquartered in Rolle, Switzerland. It is registered at 60 WINDSOR AVENUE,LONDON,UNITED KINGDOM,SW19 2RR.

Who is the current CEO of Sophia Genetics?

Jurgi Camblong of Sophia Genetics. They have also founded 1 company.

How many employees does Sophia Genetics have?

As of Sep 30, 2026, the latest employee count at Sophia Genetics is 509.

Is Sophia Genetics a funded company?

Sophia Genetics is a funded company, having raised a total of $249M across 8 funding rounds to date. The company's 1st funding round was a $***** Series A round, raised on Apr 19, 2013.

When was the latest funding round of Sophia Genetics?

Sophia Genetics' latest funding was a $***** Series F round on Oct 01, 2020, with participation from 12 investors.

Where does Sophia Genetics rank among its competitors?

Sophia Genetics ranks 4th amongst 561 active competitors, of which 90 are funded. It stands 4th in terms of total funding among its competitors. The most recent competitor to raise funding was Inocras, which secured $31M in Aug, 2026.

Who are the top competitors of Sophia Genetics?

Sophia Genetics' top competitors include Benchling, Helix and Congenica. Among them, Inocras secured the most recent funding round in August, 2026.

Sophia Genetics - 2026 Company Profile, Team, Funding & Competitors

Sophia Genetics is a public company based in Rolle (Switzerland), founded in 2011 by Jurgi Camblong and Lars Steinmetz. It operates as a Provider of artificial intelligence software for analyzing complex medical data. Sophia Genetics has raised $249M in funding from investors like Balderton Capital, Generation Investment Management and Endeavour Vision. The company has 561 active competitors, including 90 funded and 33 that have exited. Its top competitors include companies like Benchling, Helix and Congenica.

Company Details

Provider of artificial intelligence software for analyzing complex medical data. This technology platform processes genomic, radiomic, and multimodal health information to assist clinicians and researchers. It facilitates the identification of actionable insights for patients diagnosed with cancer or rare inherited disorders. The system integrates diverse health datasets to support clinical decision-making and drug development processes. By standardizing workflows and interpreting biological information, the software enables healthcare institutions to manage diagnostic challenges. The platform serves oncologists, pathologists, and geneticists by providing tools for variant analysis and clinical trial optimization. It operates as a centralized resource for managing health information while maintaining regulatory compliance and data security standards.

Website: sophiagenetics.com
Social
Phone Number: +41 **********
Registered Address: 60 WINDSOR AVENUE,LONDON,UNITED KINGDOM,SW19 2RR

Key Metrics

Founded Year

2011

Location

Rolle, Switzerland

Stage

Public

Total Funding

$249M in 8 rounds

Latest Funding Round

Series F, Oct 01, 2020, $*****

Investors

Balderton Capital & 25 more

Ranked

4^th among 561 active competitors

Employee Count

509 as on Sep 30, 2026

Investment & Acquisitions

Interactive biosoftware

Similar Companies

NeuroKaire & 36 more

Exit Details

Public

View Sophia Genetics' full profile

Sophia Genetics is associated with 2 legal entities given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
SOPHIA GENETICS, INC. CIN: 32072784716 , United States, Active	Apr 30, 2020	-	-	-
SOPHIA GENETICS LIMITED CIN: 8843207 , United Kingdom, Active	Jan 12, 2014	-	6 (As on Dec 31, 2024)

Sophia Genetics got listed on Jul 23, 2021.

Click here to take a look at Sophia Genetics's IPO in detail

Sophia Genetics has raised a total funding of $249M over 8 rounds. Its first funding round was on Apr 19, 2013. Its latest funding round was a Series F round on Oct 01, 2020 for $*****. 12 investors participated in its latest round. Sophia Genetics has 26 institutional investors.

Here is the list of recent funding rounds of Sophia Genetics:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Oct 01, 2020	9759338	Series F	1445959	4141010	7139515	5576295
Jan 03, 2019	9450595	Series E	6867366	3131663	5069823	Idinvest Partners & 2 more
Dec 14, 2018	7532648	Grant (prize money)	7315687	3534432	8074839	Tech Emerge

Access funding benchmarks and valuations. Sign up today!

View details of Sophia Genetics's funding rounds and investors

The founders of Sophia Genetics are Jurgi Camblong and Lars Steinmetz. Jurgi Camblong is the CEO of Sophia Genetics.

Here are the details of Sophia Genetics' key team members:

Jurgi Camblong: Co-Founder & CEO of Sophia Genetics.
Lars Steinmetz: Co-Founder of Sophia Genetics.

View details of Sophia Genetics's Founder profiles and Board Members

Sophia Genetics' employee count trend

Sophia Genetics has 509 employees as of Sep 26. Here is Sophia Genetics's employee count trend over the years:

Employee count trend for Sophia Genetics

Uncover Sophia Genetics' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Sophia Genetics include Benchling, Helix and Congenica. Here is the list of Top 10 competitors of Sophia Genetics, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Benchling 2012, San Francisco (United States), Series F	Provider of a cloud-based bioinformatics platform for biotech research	$412M	Altimeter Capital, Benchmark & 29 others	73/100
2nd	Helix 2015, San Francisco (United States), Series E	Provider of a genomic database for clinical research	$435M	DFJ Growth, Kleiner Perkins & 12 others	71/100
3rd	Congenica 2013, Cambridge (United Kingdom), Acquired	Developer of software for clinical genomic interpretation and variant analysis	$81.9M	IDO Investments, Xeraya Capital & 39 others	62/100
4th	Sophia Genetics 2011, Rolle (Switzerland), Public	Provider of artificial intelligence software for analyzing complex medical data	$249M	Generation Investment Management, TriplePoint Capital ... & 24 others	62/100
5th	NeuroKaire 2017, Kearny (United States), Series A	Platform offering personalized treatment for psychiatric and neurological conditions	$20M	GreyBird Ventures, Meron Capital & 6 others	61/100
6th	Latch 2021, San Francisco (United States), Series A	Provider of a web-based platform for genomic bioinformatics	$33M	Lux Capital, Coatue & 7 others	59/100
7th	Inocras 2020, San Diego (United States), Series B	AI-driven platform provides whole genome insights for cancer and rare diseases	$100M	Samsung Venture Investment, Dunamu & Partners ... & 19 others	58/100
8th	Karius 2014, Redwood City (United States), Series C	Provider of diagnostics for identifying infectious diseases using microbial DNA	$315M	Khosla Ventures, Gilde Healthcare & 16 others	58/100
9th	BostonGene 2015, Waltham (United States), Series B	Developer of cloud-based information and analytics platform to treat cancer	$200M	NEC, Japan Industrial Partners & 1 others	57/100
10th	SeqOne 2017, Montpellier (France), Series A	Provider of bioinformatics tools for the analysis of genome sequencing data	$48.8M	Elaia, Omnes Capital & 7 others	56/100